Zhitong Finance App News, Mediq (688079.SH) announced that the company plans to introduce strategic investors through its holding subsidiary Zhejiang Medikai Optics & Semiconductors Co., Ltd. (hereinafter referred to as “Optical Semiconductor Company” or “Target Company”). The strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (limited partnership) (hereinafter referred to as “Fuzhe Shaoxin”, the “investor” or “capital increase party”) plans to increase capital to the optical semiconductor company with RMB 200 million in cash according to a pre-investment valuation of 2.18 billion yuan. After the capital increase is completed, Fuzhe Shaoxin's shareholding ratio in the optical semiconductor company is 8.40%. The capital increase will be mainly used for the main business of optical semiconductor companies and other uses approved by Zhejiang Shaoxin. The price of this capital increase shall not be directly or indirectly transferred to Medicare or other entities or related parties actually controlled by it for any purpose.

Zhitong Finance App News, Mediq (688079.SH) announced that the company plans to introduce strategic investors through its holding subsidiary Zhejiang Medikai Optics & Semiconductors Co., Ltd. (hereinafter referred to as “Optical Semiconductor Company” or “Target Company”). The strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (limited partnership) (hereinafter referred to as “Fuzhe Shaoxin”, the “investor” or “capital increase party”) plans to increase capital to the optical semiconductor company with RMB 200 million in cash according to a pre-investment valuation of 2.18 billion yuan. After the capital increase is completed, Fuzhe Shaoxin's shareholding ratio in the optical semiconductor company is 8.40%. The capital increase will be mainly used for the main business of optical semiconductor companies and other uses approved by Zhejiang Shaoxin. The price of this capital increase shall not be directly or indirectly transferred to Medicare or other entities or related parties actually controlled by it for any purpose.